07/08/2019 SOURCE: www.fiercebiotech.com
Arming the immune system so it can recognize and attack solid tumors has proven to be an illusive goal. Scientists at Columbia University hope to change that with an engineered form of the bacterium EEngineered bacteria prime solid tumors for immunotherapy
-
(0)
-
Bookmark
- Comments (0)
07/08/2019 SOURCE: www.fiercebiotech.com
Pfizer and Sangamo Therapeutics have shared an upbeat update on their hemophilia A gene therapy. The update features evidence of the durability of responses to SB-525 and an early look at results in two recently-treated patients, adding to the impression that the gene therapy is a threat to assets including BioMarin’s valrox and Spark Therapeutics’ SPK-8011New data boost Pfizer, Sangamo hemophilia A gene therapy
-
(0)
-
Bookmark
- Comments (0)
07/08/2019 SOURCE: www.fiercebiotech.com
Two months after Merck announced a billion-dollar plus deal to buy out late-stage cancer biotech Peloton, some of its staffers are finding new homes. Skyhawk Therapeutics nabs Peloton exec and cancer R&D veteran as VP of oncology biology
-
(0)
-
Bookmark
- Comments (0)
05/07/2019 SOURCE: www.fiercebiotech.com
Confo Therapeutics has raised €30 million ($34 million) to take compounds targeting difficult-to-drug GPCRs into clinical development. The series A sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and performing more sensitive screensConfo raises €30M A round to target hard-to-drug GPCRs
-
(0)
-
Bookmark
- Comments (0)
Advertisement
